Bayer's Balancing Act: €2 Billion Hybrid Bond Meets a $7.25 Billion Courtroom Countdown
Published on 09/24/2026 at 05:41 | Editorial boerse-global.de
Bayer has spent months assembling a financial cushion large enough to absorb its biggest legal headache. On Wednesday, the Leverkusen-based agriculture and pharmaceutical group added another layer, pricing €2 billion in hybrid bonds after the close of trading. Both 30-year tranches drew heavy demand and were multiple times oversubscribed — a sign that fixed-income investors, at least, are willing to bet on the company's refinancing story.
Equity holders, though, are watching a different clock. The shares finished yesterday at €49.51, capping a 34% advance since the start of the year.
A Funding Stack Built Piece by Piece
The new subordinated notes slot into a broader capital-raising campaign. Bayer has already pulled in €3 billion of equity from investor Apollo for a stake in its LARC business, alongside conventional bond issues totaling $5 billion. Divestments are part of the same effort: the company agreed to hand the oncology drug Stivarga to Grünenthal for as much as €375 million. Proceeds from the hybrid placement are earmarked for general corporate purposes, shoring up the base for upcoming refinancings.
Rating agencies treat the hybrid instruments as half equity, which lifts the total outstanding hybrid volume to €6.55 billion and buys Bayer breathing room on its credit scores. Just as importantly, the structure lets management keep its pledge to avoid a dilutive share sale for now — a promise that carries real weight given the liabilities still on the books.
Where the Money Is Headed
All of it ultimately points to the glyphosate litigation in the United States. Bayer is seeking to close out the Roundup claims through a settlement worth up to $7.25 billion, a figure that translated to roughly €6.3 billion at the time the deal was struck in February. To backstop that agreement and cover maturing bonds, the group arranged an $8 billion credit line, which it intends to retire gradually through bond issuance and equity-like instruments.
Should investors sell immediately? Or is it worth buying Bayer?
One obstacle remains firmly in place: the settlement has only preliminary approval. Until a judge signs off definitively, the massive credit commitment sits on the balance sheet as a potential drag, and management must show that the chain of Apollo money, asset sales and bond placements holds without gaps.
A Supreme Court Ruling Reshapes the Battlefield
The legal backdrop shifted decisively on June 25, when the US Supreme Court ruled 7-2 in Bayer's favor in the Durnell case. The justices held that federal approval requirements take precedence over individual state regulations — a finding that stripped the legal foundation from thousands of claims alleging inadequate cancer warnings. That precedent now underpins hopes for a lasting resolution.
Pipeline Progress Runs in Parallel
While the lawyers work, Bayer is reshaping its pharmaceutical portfolio. Stivarga generated €338 million in revenue during the 2025 fiscal year. Patent protection for its active ingredient, regorafenib, expires in the European Union in 2029 and in the US in 2030, and the transaction with Grünenthal is expected to close by late 2026 or early 2027.
The company is also logging gains in its own development pipeline. A new therapy option — the first in its field in more than three decades — follows earlier approvals for type 2 diabetes patients in 2021 and for heart failure in 2025, marking the third indication cleared for the US market. There were changes on the ownership side as well.
Two Scenarios, One Verdict
The bull case rests on Bayer clearing its largest legal overhang without issuing new stock. If the US settlement wins final approval, the single biggest valuation risk of recent years would be neutralized, and attention could return to operations — where efficiency programs, including specialized software deployed with partners to speed up administrative processes, are meant to protect margins.
The bear case is built on cost and timing. The fresh 30-year tranches are expensive: the portion with a six-year non-call period carries a 5.75% coupon, while the nine-year tranche pays 6.25%. Those obligations weigh permanently on the financial result and curb future investment budgets. Should the court reject the $7.25 billion settlement in its final vote, Bayer would face a far messier landscape — the $8 billion credit line would need servicing under different terms, and the company would again be exposed to an open field of individual lawsuits. Rating agencies would likely tighten the screws, putting a conventional capital increase back on the agenda overnight.
For now, the provisional agreement holds and the stock trades above its 50-day moving average of €48.42, keeping the restructuring narrative intact. The next decisive catalyst is the final judicial ruling on the $7.25 billion settlement — the event that will determine whether Bayer's carefully constructed financing chain proves sufficient or snaps under pressure.
Ad
Bayer Stock: New Analysis - 24 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
